ROARABLE
FREE $100K
Today Screener Big Ideas Track Record 💰 $100K Arena 🎲 Predictions 🏛️ Insiders 8 Analysts
Stock Ratings / Health Care / HCM / insiders
RCUS (19) PBH (62) BHVN (44) HRMY (86) ⌘ Pro Terminal →

HUTCHMED (China) Limited (HCM) Insider, 13F Hedge Fund & Politician Buy/Sell Thermometer

$13.27 +0.91% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $13.27

HUTCHMED (China) Limited (HCM) carries a Roarable Rating of E (Strong Sell) with 34/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.

ROARABLE E • RED ALERT Cap $2.29B
📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card
⚡ INSTANT AI QUANT PREVIEW • $0 FREE TIER Click Any Pre-Computed AI Quant Specialist Briefing on HCM Below — or Connect Your Own ChatGPT / Claude
🤖 Mara Quenwick • AI Quant Lead (Click for Instant Brief) Is HCM stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
▼

As of 2026-11-03, HUTCHMED (China) Limited (NASDAQ: HCM) is rated E (Strong Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 34/100 at a spot price of $13.27 (+0.91% 1D, market cap $2.29B). Pillar breakdown: Fundamental Cash Engine 4/20, Institutional 13F & Options Flow 6/20, SEC Balance-Sheet Forensics 12/20, FRED Macro Regime Fit 5/20, and Executive Insider Alignment 7/20. Across 1015 tracked Health Care issuers, HCM ranks #621 in composite RQD confidence.

✓ Pre-computed one-to-many AI Quant brief
🤖 Ellis Vennor • AI Peer & Flow Quant (Click for Instant Brief) How does HCM compare to RCUS and PBH in the Health Care sector?
▼

Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), HCM carries a Roarable E (34/100 RQD), trailing P/E of 5.2x, gross margin of —, and ROIC of -2.5%. By comparison, RCUS (Arcus Biosciences Inc.) holds a E grade (19/100 RQD, P/E N/A, ROIC -35.0%, cap $2.32B) and PBH (Prestige Consumer Healthcare Inc.) posts a C grade (62/100 RQD, P/E 12.1x, ROIC 13.8%, cap $2.32B). Among the 5-stock peer group, HCM leads on earnings multiple (5.2x) while HRMY leads on capital efficiency (63.0% ROIC).

✓ Pre-computed one-to-many AI Quant brief
🤖 Gideon Ashmere • AI SEC 10-K Forensics (Click for Instant Brief) What are the biggest fundamental strengths and SEC risk factors for HCM?
▼

Per HCM's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001648257), HUTCHMED (China) Limited generated $548.5M in revenue (-13.0% YoY), $456.9M in net income, and -$78.8M in free cash flow against $1.75B in total assets and $68.2M in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately. Institutional options positioning shows a 50% call / 50% put premium split.

✓ Pre-computed one-to-many AI Quant brief
🤖 AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists — not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).
INTERACTIVE SCENARIO DECK:
🛡️ Portfolio Crash X-Ray
EXT / AFTER-HRS: $13.27 (-0.03%)🧬 Dilution Drag (+1.36% YoY Shares)⚙️ Cash Engine: 4/20 (E) • 0% FCF Margin
Verify 90D Bucket Audit →
📊 Historical Track Record Warning: Scores below 50 (34/100 · E) historically underperformed SPY in 71% of rolling 90-day windows (-8.7% avg 90D alpha vs SPY • 29.0% hit rate).
Audit Bucket Track Record →
RQD QUANT TACHOMETERRED ALERT • E
025507510034
2-of-3 JEV AI Jury Bearish Warning
Cash
SEC
Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw E · Rk D-
Cash (4)Whales (6)SEC (12)Macro (5)CEO (7)
Each axis scored 0–20
12M PRICE TARGET CONE-10.8% Base Target
$17 Bull$12 Base$9 Bear
📬 FREE HCM RATING-CHANGE & BRIEFING ALERTSManage / Unsubscribe
WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for HCM)Realized 20D OHLCV Swing Band: ±5.7%
Deterministic 5-Pillar Attribution (34/100 Composite)
🔍 WHY HCM SCORES 34/100 (E) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag
▲ #1 Bullish Driver: SEC 10-K Forensic Risk+12/20 pts (35% of score)

Altman Z-Score 3.63 (FORTRESS SAFE (>3.0)) • Piotroski F-Score 4/9

▲ #2 Bullish Driver: Insider Conviction & Share Dilution+7/20 pts (21% of score)

SEC Form 4 / 13F Thermometer: 35% Net Buy • Dilution Drag (+1.36% YoY Shares)

▼ #1 Drag / Risk Factor: Cash Engine Quality4/20 pts (-16 pt drag)

Capital intensity & 0% operating margin leave 16 pts on the table

📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current
Q1 (-3Q)
42
Grade D$13.50+9.2% Next Q
Q2 (-2Q)
39
Grade E$14.74-6.4% Next Q
Q3 (-1Q)
37
Grade E$13.80-3.8% Next Q
Current
34
Grade E$13.27-8.7% Hist 90D α
Trajectory: D (42) → E (34)Full Audit →
⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER

⚔️ Adversarial Opposing Case: What Could Spark a HCM Turnaround Squeeze

Gideon Ashmere Forensic Desk →

While HCM currently carries a cautious 34/100 (E) rating due to Cash Engine Quality (4/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.

🚀 Contrarian Squeeze Trigger #1

Established market leader in Health Care with deep daily trading liquidity.

🚀 Contrarian Squeeze Trigger #2

Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($13.69) and Max Pain ($13.93) forces dealer call-delta covering toward $17.15.

🚀 Contrarian Squeeze Trigger #3

Forensic Repair Trigger: Halting share dilution (Dilution Drag (+1.36% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.

🎲 LIVE PREDICTION MARKET ODDS TIED TO $HCM• $2.4M Crowd Pool • Kalshi / Polymarket Composite
Contract: “HCM Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”
YES 34%NO 66%Trade / Inspect Odds →
SEC FORM 4 × 13F HEDGE FUNDS × CONGRESSIONAL STOCK ACT

HCM Smart-Money Thermometer: NET EXECUTIVE TRIMMING / PROFIT-TAKING

Explore All 13F & Congress Whales →
▲ Disclosed Buys: 0 ($0)▼ Disclosed Sales: 0 ($0)

Wide-Open SEC Form 4, 13F & Congressional Disclosure Ledger (HCM)

No recent open-market Form 4 cluster sales or emergency dumps flagged on HCM. Visit the Global 13F & Congressional Whale Ledger for cross-market smart-money filings.

ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring HCM)

  • ✓Walkthrough of HCM's RQD Radar, SEC cash-conversion gap & downside invalidation levels
  • ✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
  • ✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks
RQD INSIDER CLUB WAITLIST$49/YR PLANNED
Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?
Join Founding VIP Waitlist (No Card Required) →$100K Arena
HCM // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: +0.38%▲ ASCENDING CHANNEL
2026-11-03O $13.59H $13.59L $13.15C $13.27VOL 33.5K
RES: $16.66SUP: $12.73SMA50: $13.69SMA200: $13.20
$15.49$13.94$12.39$10.84$9.29RES $16.66SUP $12.73$13.272026-05-042026-06-172026-08-042026-09-182026-11-03
PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

HCM Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 HCM Butterfly Map → + Track HCM →
Share Count & Dilution Monitor

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle
-13.3%/yr Implied 5Y Growth

vs. -13.0% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger

No active Ellis Vennor swing setup published on HCM today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for HCM. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video
🎬 No recent verified company-specific video clip queued for HCM today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →
DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (HCM)

Health Care Rank #621 of 1015 ⚔️ RCUS vs HCM Full Matrix →

1. Head-to-Head Health Care Peer Comparison (HCM vs. RCUS, PBH, BHVN, HRMY)

Industry: Biotechnology: Pharmaceutical Preparations (489 Tracked Issuers)

Across 1015 tracked Health Care securities in the Roarable RQD universe, HUTCHMED (China) Limited (HCM) ranks #621 by composite RQD confidence (34/100, grade E) and #232 by equity capitalization ($2.29B). Within this direct 5-issuer industry benchmark cohort, HCM leads on earnings valuation at 5.2x trailing P/E, while HRMY leads on capital efficiency and profitability with 63.0% ROIC and 77.2% gross margin. HRMY currently holds the highest overall quantitative score in the immediate peer group at 86/100 (A) compared with HCM at 34/100 (E).

Ticker / Company Roarable Grade RQD Score Trailing P/E Gross Margin ROIC 1D Change Market Cap Head-to-Head
HCM ACTIVE
HUTCHMED (China) Limited
E 34/100 5.2x — -2.5% +0.91% $2.29B Benchmark Subject
RCUS
Arcus Biosciences Inc.
E 19/100 — — -35.0% -1.87% $2.32B /rcus-vs-hcm →
PBH
Prestige Consumer Healthcare Inc.
C 62/100 12.1x 54.7% 13.8% +1.37% $2.32B /pbh-vs-hcm →
BHVN
Biohaven Ltd.
D 44/100 — — -35.0% -1.69% $2.33B /bhvn-vs-hcm →
HRMY
Harmony Biosciences Holdings Inc.
A 86/100 14.2x 77.2% 63.0% -2.19% $2.26B /hrmy-vs-hcm →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0001648257 ↗

In its most recent audited fiscal period (FY2025, filed 2025-12-31), HUTCHMED (China) Limited (HCM) reported GAAP revenue of $548.5M (-13.0% vs. FY2024 revenue of $630.2M , and -34.5% cumulative change since FY2023) , GAAP net income of $456.9M, operating cash flow of -$64.7M, and free cash flow of -$78.8M (-352.0% YoY). On the balance sheet, HCM closed FY2025 with $1.75B in total assets against $68.2M in total debt (Altman Z-Score: 3.63, Piotroski F-Score: 4/9).

Fiscal Period Filing Date Revenue Net Income Operating Cash Flow Free Cash Flow Total Assets Total Debt
FY2025 (FY) 2025-12-31 $548.5M $456.9M -$64.7M -$78.8M $1.75B $68.2M
FY2024 (FY) 2024-12-31 $630.2M $37.7M $497.0K -$17.4M $1.27B $59.4M
FY2023 (FY) 2023-12-31 $838.0M $100.8M $219.3M $219.3M — —

3. HCM Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is HCM stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

As of 2026-11-03, HUTCHMED (China) Limited (NASDAQ: HCM) is rated E (Strong Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 34/100 at a spot price of $13.27 (+0.91% 1D, market cap $2.29B). Pillar breakdown: Fundamental Cash Engine 4/20, Institutional 13F & Options Flow 6/20, SEC Balance-Sheet Forensics 12/20, FRED Macro Regime Fit 5/20, and Executive Insider Alignment 7/20. Across 1015 tracked Health Care issuers, HCM ranks #621 in composite RQD confidence.

How does HCM compare to RCUS and PBH in the Health Care sector?

Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), HCM carries a Roarable E (34/100 RQD), trailing P/E of 5.2x, gross margin of —, and ROIC of -2.5%. By comparison, RCUS (Arcus Biosciences Inc.) holds a E grade (19/100 RQD, P/E N/A, ROIC -35.0%, cap $2.32B) and PBH (Prestige Consumer Healthcare Inc.) posts a C grade (62/100 RQD, P/E 12.1x, ROIC 13.8%, cap $2.32B). Among the 5-stock peer group, HCM leads on earnings multiple (5.2x) while HRMY leads on capital efficiency (63.0% ROIC).

What are the biggest fundamental strengths and SEC risk factors for HCM?

Per HCM's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001648257), HUTCHMED (China) Limited generated $548.5M in revenue (-13.0% YoY), $456.9M in net income, and -$78.8M in free cash flow against $1.75B in total assets and $68.2M in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately. Institutional options positioning shows a 50% call / 50% put premium split.

Where is HCM trading relative to its 50-day, 200-day, and 52-week technical levels?

HCM last traded at $13.27 (+0.91% on volume of 47,969 shares), positioning the stock -3.07% below its 50-day simple moving average ($13.69) and +0.53% above its 200-day simple moving average ($13.20). Across its 52-week range of $9.77 to $16.33, HCM sits at the 53.4% percentile with a 14-day RSI of 42.4 (NEUTRAL RANGE) and an implied next-earnings move of ±5.7% ($12.51 to $14.03).

Direct Sub-Reports: HCM RQD Cockpit HCM 12M Forecast HCM Earnings & Move HCM Dividends & DRIP HCM Insiders & 13F HCM Whale Options HCM Profit Sankey HCM News & Why
ROARABLE RATING BRIEF • RQD 34/100 (E) ✓ SEC XBRL & RQD VERIFIED

HCM — HUTCHMED (China) Limited: What the Facts Mean to a Prospective Investor

Methodology: RQD v6.2 Deterministic 5-Pillar & SEC XBRL Audit
Updated: 2025-12-31

1. Roarable Rating Brief: What This Means to a Prospective Investor

HUTCHMED (China) Limited (HCM) earns a live Roarable RQD composite score of 34/100, corresponding to a E letter grade (Roarable Strong Sell) at a spot price of $13.27 (+0.91% 1D, market capitalization $2.29B).

  • Fundamental Cash Engine (4/20): Anchored by return on invested capital (ROIC) of -2.5%, gross margin of —, operating margin of -7.1%, and free cash flow yield of -3.32%.
  • Whale 13F & Options Flow (6/20) + Insider Conviction (7/20): Tracks institutional 13F accumulation, CBOE options call/put positioning, and SEC Form 4 / Congressional PTR filings.
  • Macro Regime Fit (5/20) + Forensic Balance Sheet (12/20): Incorporates a 1.00x equity beta, Altman Z-Score of 3.63, Piotroski F-Score of 4/9, and Debt/Equity of 0.06x.

2. Business Model, Unit Margins & SEC Financial Trajectory

HUTCHMED (China) Limited trades on NASDAQ under HCM and is classified in the Health Care sector, Biotechnology: Pharmaceutical Preparations industry, per the SEC profile. The company reported revenue of $548.5M for FY 2025, indicating a commercial operation generating sales.

In its latest audited SEC EDGAR 10-K filing for FY2025 (filed 2025-12-31), HUTCHMED (China) Limited (HCM) reported $548.5M in annual revenue (up from $630.2M in FY2024, -13.0% YoY) and $456.9M in GAAP net income. Over the multi-year SEC filing window from FY2023 ($838.0M revenue, $100.8M net income) through FY2025, HCM scaled operating cash flow to -$64.7M and free cash flow to -$78.8M, backed by $1.75B in total assets against $68.2M in total debt.

3. Institutional Bull vs. Bear Thesis & Valuation Tradeoff

  • 🐂 Primary Bull Case (E • RQD 34/100): Established market leader in Health Care with deep daily trading liquidity. Free cash flow yield of -3.32% and institutional whale pillar of 6/20. With Fundamental Cash Engine at 4/20 and Institutional Whale Flow at 6/20, sustained execution supports upside toward the upper end of the $9.77 – $16.33 52-week range.
  • 🐻 Primary Bear Case & Valuation Risk: Company executives have done more routine share selling than personal cash buying lately. Investors must weigh 5.2x trailing P/E against -7.1% operating margins and a 1.00x macro beta.

4. 2nd-Order Butterfly Ripples & Key Questions to Watch

Operating in Biotechnology: Pharmaceutical Preparations (Health Care), HCM carries a macro regime beta of 1.00 and gross margin of —.

  • Key Question #1: Can HCM sustain or expand its -7.1% operating margin and -2.5% ROIC against Biotechnology: Pharmaceutical Preparations peers over the next 4 quarters?
  • Key Question #2: Following FY2025 revenue of $548.5M and free cash flow of -$78.8M, how will capital allocation balance growth reinvestment against $68.2M in total debt?
  • Key Question #3: How sensitive is HCM's 4.8x forward P/E multiple to Health Care capital spending cycles and macro interest-rate shifts (Beta 1.00x)?

HCM Live News Feed, Press Releases & Catalyst Wire

Real-time company headlines, analyst actions, and sector developments for HUTCHMED (China) Limited (HCM) • Click "Debate This Headline" to argue it in the Roar Pit below

💬 Jump to HCM Debate Forum (3) ↓
🔥 THE ROAR PIT • LIVE COMMUNITY DEBATE 3 Active Posts & Replies

HCM Bull vs. Bear Conversation Board — What's Your Call at $13.27?

🐂 67% BULLISH CONVICTION COMMUNITY TUG-OF-WAR ON HCM 🐻 33% BEARISH CONVICTION
1. Pick Your Side on HCM:
💡 Tip: Back up your call with a price target or RQD metric to get upvoted to the top.
QU QuantViper RQD DEBATE OPENER • Systematic Momentum Desk 🐂 BULLISH 🎯 Target: $15.78 (+20.0%)
📌 Pinned Debate

A reported GSK deal with up to $1.185B in potential milestones could strengthen the cash engine that currently scores 4/20.

Long HCM at $13.15 targeting $15.78. A reported GSK deal with up to $1.185B in potential milestones could strengthen the cash engine that currently scores 4/20.. Institutional whale score is 6/20 and the risk/reward vs. the $9.77 52-week low is skewed heavily in favor of bulls.

EarningsSniper 🐂 BULL

@RiskArb_Desk Shorting a 6/20 institutional whale-flow stock at $13.15 is dangerous when funds are rotating into Health Care.

RI RiskArb_Desk RQD DEBATE OPENER • Hedged Event Driven 🐻 BEARISH 🎯 Target: $9.86 (-25.0%)
Spot @ $13.15

ROIC of -2.5% and FCF yield of -3.32% show the business is not currently converting its reported earnings into cash.

Here is the bear case nobody on the bull side wants to address on HCM: ROIC of -2.5% and FCF yield of -3.32% show the business is not currently converting its reported earnings into cash.. At 5.2x trailing P/E, even a small guidance miss in Biotechnology: Pharmaceutical Preparations triggers a 12-15% air pocket.

LIVE TAPE SPY $752.10 -1.80% QQQ $681.09 -3.60% DIA $519.34 -1.08% IWM $279.14 -1.68% NVDA $202.06 -1.26% AAPL $338.32 -1.83% MSFT $507.12 -2.83% TSLA $403.82 +1.00% PLTR $178.34 -3.13% SOFI $16.60 -0.95% IBIT $43.35 -5.42% GLD $361.65 -3.59%